Are Semaglutide Tablets FDA Approved for Weight Loss?

By Matt Waterman · 2026-09-12

Semaglutide tablets are FDA approved for the treatment of type 2 diabetes under the brand name Rybelsus, but they are not currently FDA approved for chronic weight management. For patients seeking weight loss, the FDA has only approved the injectable form of semaglutide, known as Wegovy, which is administered weekly. While clinicians may prescribe oral semaglutide off-label or utilize compounded versions for weight loss, it is essential to understand the regulatory landscape and clinical evidence surrounding these delivery methods.

How Does the FDA Approval for Oral Semaglutide Work?

The distinction between an FDA approved drug and an FDA approved indication is critical for patients navigating the GLP-1 program. Currently, the FDA has granted approval for Rybelsus (oral semaglutide) specifically for improving glycemic control in adults with type 2 diabetes. The approval was based on the PIONEER clinical trial program, which demonstrated the drug effectiveness in lowering A1C levels. However, the FDA has not extended this approval to include chronic weight management for individuals without diabetes, even if they meet BMI eligibility requirements.

For weight loss, the gold standard remains the injectable route. The FDA approved Wegovy for weight loss in 2021 following the STEP 1 clinical trial published in the New England Journal of Medicine, which showed an average weight loss of 14.9 percent over 68 weeks. Because the oral version was developed and studied primarily for diabetes, its use for weight loss is considered off-label. Many patients prefer tablets to avoid needles, but they must weigh this against the fact that the oral formulation is not yet indicated for weight loss by federal regulators.

The Science of Bioavailability: Tablets vs. Injections

One of the primary reasons semaglutide was initially an injectable medication is because GLP-1 receptor agonists are large peptide molecules that are easily degraded by stomach acid. To make buy semaglutide online in tablet form possible, the medication is formulated with an absorption enhancer called SNAC (salcaprozate sodium). Even with this enhancer, the bioavailability of oral semaglutide is approximately 0.05 percent to 1 percent, meaning only a tiny fraction of the drug reaches the bloodstream.

This low bioavailability necessitates a strict administration protocol. Patients must take the tablet at least 30 minutes before the first food, beverage, or other oral medications of the day, with no more than 4 ounces of plain water. Failure to follow this protocol can render the medication ineffective. In contrast, injectable semaglutide and buy tirzepatide online bypass the digestive system entirely, providing 100 percent bioavailability and more consistent appetite regulation throughout the week.

Comparing Oral and Injectable Semaglutide Efficacy

When looking at clinical data, the weight loss outcomes for the FDA approved injectable form are currently superior to the FDA approved oral form used for diabetes. While Rybelsus does induce weight loss in many patients, it was not the primary endpoint of its regulatory trials. In the PIONEER trials, patients lost significantly less weight than those in the STEP trials using higher-dose injections. However, a recent 2023 trial published in The Lancet (OASIS 1) studied a higher 50mg dose of oral semaglutide specifically for weight loss, showing results comparable to injections. This 50mg dose is not yet commercially available as an FDA approved product.

Feature	Oral Semaglutide (Rybelsus)	Injectable Semaglutide (Wegovy)
FDA Approved for Weight Loss	No (Off-label only)	Yes
Administration Frequency	Daily	Weekly
Bioavailability	Low (0.05-1%)	High (100%)
Fasting Requirement	Yes (30 minutes)	No
Common Side Effects	Nausea, Diarrhea, Vomiting	Nausea, Constipation, Injection site reaction

Understanding Compounded Oral Semaglutide

Due to ongoing shortages of brand-name GLP-1 medications, many patients turn to compounded formulations. It is vital to note that compounded semaglutide is not FDA approved. While the FDA allows state-licensed compounding pharmacies to produce versions of drugs that are on the official shortage list, these versions do not undergo the same pre-market rigorous testing for safety, purity, or efficacy as brand-name drugs. At HELiXVi, we ensure that if a patient chooses a compounded route, it is through a reputable, licensed pharmacy.

Compounded oral options often come in sublingual (under the tongue) or rapidly dissolving tablet forms. The goal of these formulations is to improve absorption by bypassing the harsh environment of the stomach. However, clinical data on the exact bioavailability of sublingual semaglutide is more limited than the data available for the FDA approved tablet. Patients should consult a live AI video doctor to discuss whether a compounded formulation is appropriate for their specific medical history and weight loss goals.

Side Effects and Safety Considerations

Regardless of the delivery method, GLP-1 receptor agonists work by mimicking the GLP-1 hormone, which slows gastric emptying and signals satiety to the brain. This mechanism of action frequently leads to gastrointestinal side effects. Patients taking oral semaglutide often report nausea, abdominal pain, and diarrhea, particularly during the first few weeks of treatment or during a dose increase.

Because the oral version is taken daily, the side effects can be more persistent for some, whereas injectable patients might experience a peak of symptoms 24 to 48 hours after their weekly dose. Serious but rare risks include pancreatitis, gallbladder problems, and kidney issues. A physician will review your medical history, including any family history of medullary thyroid carcinoma, to ensure the medication is safe for you. For more detailed safety information, you can read a related HELiXVi guide on managing GLP-1 side effects.

Telehealth Access and BMI Eligibility

Accessing weight loss treatment through telehealth has become the standard for modern care. To qualify for semaglutide, whether oral or injectable, patients typically must meet BMI eligibility criteria: a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related condition such as hypertension or high cholesterol. Telehealth platforms like HELiXVi streamline this process by providing digital screening and physician consultations from the comfort of your home.

Cost and insurance are also major factors in the decision between oral and injectable forms. Many insurance plans do not cover weight loss medications, and the out-of-pocket cost for brand-name Rybelsus or Wegovy can be substantial. Compounded options are often more affordable, but they lack the insurance coverage and FDA backing of brand-name products. Your provider can help you navigate these financial considerations during your consultation.

The Future of Oral GLP-1 Therapy

The pharmaceutical industry is heavily invested in developing more effective oral GLP-1 receptor agonists. Beyond semaglutide, companies are testing tirzepatide tablets and other small-molecule agonists that do not require the strict fasting protocols of current peptides. The goal is to provide a convenience that matches the efficacy of the 15 to 20 percent weight loss seen in injectable trials. We cover this in more detail in how much do semaglutide tablets cost.

Until a high-dose oral semaglutide tablet is officially FDA approved for weight loss, patients must choose between the convenience of a daily pill and the proven potency of a weekly injection. Both routes require a commitment to lifestyle changes, including diet and exercise, to maintain long-term results. If you are ready to begin your journey, a HELiXVi physician determines what is appropriate for you. To get started, visit our GLP-1 program.

This article is educational and is not a substitute for individual medical advice. A HELiXVi physician determines what is appropriate for you.